Biocryst Pharmaceuticals (BCRX) FCF Margin (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) posted FCF Margin of 39.89% for Q1 2026, down 100.1% on a QoQ basis from 41386.72% in Q4 2025, and down 2099.0% year-over-year from 2.0% in Q1 2025.
Biocryst Pharmaceuticals (BCRX) FCF Margin (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' FCF Margin history runs 17 years deep, the most recent figure standing at 39.89% for Q1 2026.
- Quarterly FCF Margin fell 2099.0% year-over-year to 39.89% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 64.99% (up 7008.0% YoY) and the FY2025 annual result came in at 39.64%, up 5118.0% from the prior year.
- FCF Margin was 39.89% for Q1 2026 at Biocryst Pharmaceuticals, down from 41386.72% in the prior quarter.
- Across five years, FCF Margin topped out at 41386.72% in Q4 2025 and bottomed at 156.65% in Q1 2022.
- A 5-year average of 2407.33% and a median of 23.37% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2025 — FCF Margin jumped 4139035 bps — and 2026, when it sank 2099 bps.
- Biocryst Pharmaceuticals' FCF Margin stood at 30.64% in 2022, then surged by 74 bps to 7.82% in 2023, then jumped by 54 bps to 3.62% in 2024, then soared by 1142787 bps to 41386.72% in 2025, then slumped by 100 bps to 39.89% in 2026.
- Business Quant data shows BCRX's FCF Margin at 39.89% in Q1 2026, 41386.72% in Q4 2025, and 25.74% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -5.22% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 12.86% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -5.35% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 46.54% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 9.93% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 17.73% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.77% |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -39.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.89% |
| Dec 31, 2025 | 41,386.72% |
| Sep 30, 2025 | 25.74% |
| Jun 30, 2025 | 24.63% |
| Mar 31, 2025 | -18.91% |
| Dec 31, 2024 | -3.62% |
| Sep 30, 2024 | 6.66% |
| Jun 30, 2024 | -1.04% |
| Mar 31, 2024 | -58.13% |
| Dec 31, 2023 | -7.82% |
| Sep 30, 2023 | -24.08% |
| Jun 30, 2023 | -23.37% |
| Mar 31, 2023 | -69.31% |
| Dec 31, 2022 | -30.64% |
| Sep 30, 2022 | -43.02% |
| Jun 30, 2022 | -42.73% |
| Mar 31, 2022 | -156.65% |
| Dec 31, 2021 | -71.18% |
| Sep 30, 2021 | -57.67% |
| Jun 30, 2021 | -52.49% |